From Clinical Trials to Market Highs, This Outsourcer May Be Just Getting Started

A healthcare outsourcer is surging on stronger guidance and bullish technicals.

For investors seeking durable growth, momentum in clinical research may offer one of the market’s cleaner setups right now.

Breakout Watchlist Ready (Sponsored)

5 Hidden Opportunities Ready to Surge

When markets shift, opportunities emerge. But the best ones rarely stay hidden for long.

Our analysts have pinpointed 5 companies that stand out for their fundamentals, momentum, and potential to double from here.

You’ll find them inside the new 5 Stocks Set to Double report—free for a limited time.

Past versions of this report uncovered stocks that went on to massive gains of +175%, +498%, even +673%.¹

Today, you can download your copy instantly.

But once the clock strikes midnight, this free access closes.

[Grab your free report now]

Big winners don’t wait. Neither should you.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Catalyst Pharmaceuticals | CPRX

Price: $20.39

Catalyst shares have declined by over 6% year-to-date, but the investment case has just strengthened with a patent settlement that extends exclusivity for FIRDAPSE, its flagship drug, into 2035.

The move eliminates a cloud of uncertainty, following similar deals with Teva and Inventia, and strengthens the company’s long-term revenue outlook.

Recent updates to clinical guidelines also highlight FIRDAPSE as a recommended treatment, supporting physician awareness and adoption.

Even with these wins, the stock remains tied to a single product that still accounts for two-thirds of sales.

That concentration keeps risk elevated, and the shares continue to trade near 52-week lows despite upside potential.

Analysts estimate fair value closer to $34, more than 60% above the current price, reflecting confidence in market share growth from broader diagnosis.

Why It Matters: The settlement provides Catalyst with greater visibility into its cash flow, but investors should carefully weigh the concentration risk.

For those willing to hold through volatility, the disconnect between price and projected revenue could make pullbacks attractive entry points.

Netflix | NFLX

Price: $1,231.52

Netflix is up nearly 38% in 2025, outpacing both the S&P 500 and its media peers. Analysts expect EPS to climb 27% this quarter and more than 30% for the full year, driven by double-digit revenue growth.

The company’s expansion into ad-supported tiers and international markets continues to underpin bullish estimates.

Zacks currently ranks the stock as a “Strong Buy,” citing stable revisions and consistent earnings beats.

Valuation remains a sticking point, with a forward P/E north of 50 and a Style Score of “F” on value. The premium reflects Netflix’s track record of execution, but it leaves little margin for error.

Any slowdown in subscriber growth or pricing pressure could trigger a sharp pullback.

Why It Matters: Momentum is on Netflix’s side, but entry points matter at these levels.

Long-term investors may want to wait for dips, while momentum traders could see near-term upside as estimates remain intact and international streaming adoption accelerates.

Hidden Stock Move (Sponsored)

5 AI Stocks With Explosive Potential

AI’s impact is accelerating — reshaping industries and creating massive new wealth opportunities.

In our newest report, you’ll discover 5 stocks positioned at the center of this transformation.

Among them: a sleeper stock quietly gaining ground while remaining under Wall Street’s radar.

The earlier you see these opportunities, the greater your potential edge.

[Download the free report before it’s gone]

Walgreens Boots Alliance | WBA

Price: $11.98

Walgreens has staged a surprising rebound, up 30% year-to-date, driven by progress on its pending merger with Rite Aid.

A key milestone was reached this week, with bondholders tendering more than 90% of the outstanding notes, simplifying the balance sheet and paving the way for the deal to close.

The settlement is scheduled for August 28, keeping the transaction on track.

Even with merger momentum, Walgreens faces challenges. The company carries about $30 billion in debt and has seen its retail pharmacy business pressured by cost inflation and competition.

However, management has expanded its specialty pharmacy network, positioning for higher-margin growth, and bondholder participation suggests institutional confidence in the restructuring plan.

Why It Matters: The merger could provide Walgreens with a fresh start under new ownership, offering more flexibility to streamline operations.

Speculative investors may see upside if integration runs smoothly, but execution risk and leverage remain key overhangs.

Etsy | ETSY

Price: $53.87

Etsy has climbed 48% in recent months and now trades near $54, recovering from 52-week lows around $40.

The marketplace operator has benefited from renewed investor interest in mid-cap growth, with profit expected to nearly double over the next two years.

Optimism around higher cash flow and margin expansion has supported the rebound.

Still, the stock trades at a P/E ratio above 40, significantly higher than its multiline retail peers. While growth expectations are strong, valuation leaves little cushion if consumer spending softens.

Etsy’s high beta also makes it more vulnerable to swings in market sentiment.

Why It Matters: For investors who believe in long-term e-commerce penetration and Etsy’s niche positioning, momentum could carry further.

But the elevated valuation suggests patience may be rewarded with better entry points if volatility returns.

Medpace Holdings | MEDP

Price: $473.30

Shares of Medpace have surged over 40% this year, reaching record highs after a strong second quarter.

Revenue rose 14% year-over-year to $603 million, while earnings topped estimates and margins expanded.

Management raised full-year guidance well above consensus, projecting up to 19.5% sales growth in 2025.

Technical momentum has confirmed the fundamentals, with the stock flashing a bullish “golden cross.”

The company has benefited from broad outsourcing trends in clinical research, with new business awards rising and a book-to-bill ratio above 1.0.

Institutional demand has also increased, with funds owning about two-thirds of outstanding shares.

Medpace continues to repurchase stock aggressively, signaling confidence in long-term growth.

Why It Matters: Outsourcing in clinical trials is a durable secular theme, and Medpace is executing well.

While the stock is not cheap at 35x earnings, the combination of growth, profitability, and technical strength may appeal to investors seeking exposure to healthcare innovation.

There are catalysts out there, including biotech exclusivity, healthcare outsourcing, streaming momentum, retail M&A, and e-commerce recovery.

The common thread is clarity on growth drivers is commanding premium valuations, while turnarounds remain speculative but potentially rewarding.

Investors who balance exposure to both themes, defensible growth and discounted rebuilds, may be best positioned for the next leg of the market.

Stat of the Day – $46.7 Billion
Nvidia set a new quarterly sales record in July, with revenue climbing to $46.7 billion.

Data-center sales rose 56% to $41.1 billion, underscoring the relentless demand for AI, although the results fell just shy of analyst expectations.

The muted outlook weighed on shares, but the long-term capital expenditure (capex) pipeline from hyperscalers remains enormous, with CEO Jensen Huang estimating $3–4 trillion of AI spending over the next five years.